All times are listed in CEST (Central European Summer Time)
- Manuela Schmidinger (Vienna, Austria)
- Viktor Grünwald (Essen, Germany)
700O - Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)
- Maxime Meylan (Paris, France)
Abstract
Background
The NIVOREN GETUG-AFU 26 study reported safety and efficacy of N in metastatic (m-) ccRCC patients (pts) in a “real world setting”. A translational research program including gene expression signatures was launched to identify biomarkers for outcome to N.
Methods
Among the 324 pts included in the NIVOREN translational cohort, RNA-sequencing was performed on 79 FFPE primary ccRCCs. We first evaluated the impact of Teff and Angio signatures on the outcome, based on median mRNA expression values, as described in the IMmotion 150 RCC trial. To better characterize the tumor microenvironment, we performed an unsupervised analysis using MCP-Counter to classify tumors according to their infiltration by 8 immune (I) and 2 stromal (S) (fibroblasts and endothelial) cell populations. Outcomes were the response rate (RR, best response determined by complete or partial response) and PFS.
Results
Angio– and Teff signatures were not predictive of outcomes on N when applied separately. However, combination of these two signatures revealed that the most aggressive tumors Teff-high/Angio-low and Teff-low/Angio-low were significantly associated with RR and PFS (Table).Unsupervised classification identified 5 KIC subtypes (A to E). CD8-high/S-low (KIC C+E) tumors were associated with higher RR and longer PFS compared to I-low/S-low (KIC A), I-low/S-high (KIC B) and I-high/S-high (KIC D) tumors (Table). Principal component analysis showed a similar contribution of KIC stromal cells and the Angio signatures in worst outcome tumors. The KIC classification identified tumor microenvironments linked to good outcomes on N and unraveled the deleterious clinical impact of the potential immunosuppression exerted by neutrophils, fibroblasts and endothelial cells.
RR P-value Fisher exact Median PFS [CI95%] (mo) P-value Log rank Teff-high/Angio-low 8/17 (47%) 0.01 10.1 [2.7; NE] 0.0005 Teff-high/Angio-high 4/22 (18%) 4.1 [2.6;5.6] Teff-low/Angio-high 5/16 (31%) 3.2 [2.4;NE] Teff-low/Angio-low 1/21 (5%) 2.6 [2.1;2.8] KIC C-E 10/21 (48%) 0.005 11.4 [2.4;NE] 0.03 KIC A-B-D 8/55 (15%) 2.8 [2.7;4.2]
Conclusions
We report for the first time from a prospective trial that Immune high/angiogenesis and stromal low signatures likely predict nivolumab efficacy in m-ccRCC patients.
Clinical trial identification
NCT03013335.
Legal entity responsible for the study
Unicancer.
Funding
Institut National du Cancer and Bristol-Myers Squibb.
Disclosure
B. Beuselinck: Honoraria (self), Research grant/Funding (self): Bristol-Myers Squibb ; Honoraria (self): Merck; Honoraria (self): Pfizer; Honoraria (self): Ipsen; Honoraria (self): AstraZeneca. Y. Vano: Honoraria (self), Travel/Accommodation/Expenses: Bristol-Myers Squibb; Honoraria (self), Travel/Accommodation/Expenses: Pfizer; Honoraria (self): Novartis; Honoraria (self): Ipsen; Honoraria (self): Merck; Honoraria (self), Travel/Accommodation/Expenses: MSD; Honoraria (self): Janssen; Honoraria (self): Sanofi; Honoraria (self): Astellas; Honoraria (self), Travel/Accommodation/Expenses: Roche. N. Rioux Leclercq: Travel/Accommodation/Expenses, conference support: Pfizer; Travel/Accommodation/Expenses, conference support: Bristol-Myers squibb; Travel/Accommodation/Expenses, conference support: AstraZeneca. N. Chaput: Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Roche; Honoraria (self): Sanofi; Honoraria (self): Cytune Pharma; Honoraria (self): AstraZeneca. C. Chevreau: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Advisory/Consultancy: Novartis. M. Gross Goupil: Honoraria (self), Travel/Accommodation/Expenses: Bristo-Myers Squibb; Honoraria (self), Travel/Accommodation/Expenses: MSD; Honoraria (self), Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Travel/Accommodation/Expenses: Roche; Honoraria (self), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Travel/Accommodation/Expenses: Ipsen. A. Fléchon: Honoraria (self), Travel/Accommodation/Expenses: Bristol-Myers Squibb; Honoraria (self), Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Travel/Accommodation/Expenses: Novartis. B. Laguerre: Travel/Accommodation/Expenses: Pfizer; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Ipsen; Honoraria (self): Roche; Honoraria (self): MSD. B. Escudier: Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Roche; Honoraria (self): Ipsen; Honoraria (self): Eisai; Honoraria (self): EUSA Pharma; Honoraria (self): Oncorena. L. Albiges: Honoraria (institution): Pfizer; Honoraria (institution): Novartis; Honoraria (institution): Bristol-Myers Squibb; Honoraria (institution): Ipsen; Honoraria (institution): Roche; Honoraria (institution): AstraZeneca; Honoraria (institution): Amgen; Honoraria (institution): Astellas; Honoraria (institution): Exelixis; Honoraria (institution): Corvus Pharmaceuticals; Honoraria (institution): Peloton therapeutcis; Honoraria (institution): MSD; Honoraria (institution): Merck. All other authors have declared no conflicts of interest.
701O - Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing
- Zeynep B. Zengin (Duarte, United States of America)
Abstract
Background
ctDNA analysis is a non-invasive method used to assess tumor-derived genomic alterations (GAs). Previous work in mRCC has shown that ctDNA profiles evolve with treatment in mRCC. We utilized a commercially available ctDNA assay to identify common GAs in mRCC and compared ctDNA and tissue-based GAs in pts with mRCC.
Methods
We retrospectively identified consecutive pts with mRCC who underwent ctDNA testing using a clinically-validated 73- to 74-gene panel (Guardant360) between November 2016–December 2019. The targeted next-generation sequencing (NGS) ctDNA assay included analysis of sequence alterations, small insertions/deletions, amplifications, and fusions. In a subset of pts, GAs identified with ctDNA were compared to GAs detected via tissue-based platforms with using either whole-exome sequencing (Ashion Analytics) or targeted NGS (Foundation Medicine). Tissue test results included variants of unknown significance (VUS), as some clinically relevant alterations were classified as such.
Results
Across 847 mRCC pts (600 male, 247 female), ≥1 GAs were detected in 669/929 (72%) ctDNA samples. After excluding VUS and synonymous variants, TP53 (37%), VHL (22%), and EGFR (6%) were the most frequently altered genes in ctDNA. Tissue DNA analysis of 47 pts was also assessed; VHL (63.8%), PBRM1 (44.7%) and SETD2 (31.9%) were most frequently mutated (the latter two genes were not included on the ctDNA assay). Median time between tissue and ctDNA assays was 15.3 months (IQR, 7.5-29.8). When restricted to only the genes included on the ctDNA assay, a total of 154 GAs were found across both assays. Of these, 41 (26.6%) GAs were exclusive to blood, 92 (59.7%) were exclusive to tissue, and 21 (13.6%) were found on both platforms. The cumulative concordance rate between ctDNA and tissue DNA samples was 96.6%. Sequential ctDNA assessment was available in 65 pts; results will be presented at the meeting.
Conclusions
With the largest mRCC cohort to date, our study shows ctDNA analysis is feasible and highly concordant with tissue genomic analysis. Exclusive GAs found on both platforms suggests tumor evolution over time and treatment, which may assist in guiding treatment selection in mRCC.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Weipert: Shareholder/Stockholder/Stock options, Full/Part-time employment: Guardant Health. J. Hsu: Shareholder/Stockholder/Stock options, Full/Part-time employment: Guardant Health. S. Pal: Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy: Novartis; Advisory/Consultancy, Research grant/Funding (institution): Aveo; Advisory/Consultancy: Genentech; Advisory/Consultancy, Research grant/Funding (institution): Exelis; Advisory/Consultancy, Research grant/Funding (institution): Bristol Myers Squibb; Advisory/Consultancy: Astellas Pharma; Advisory/Consultancy: GlaxoSmithKline; Advisory/Consultancy, Research grant/Funding (institution): Eisai; Advisory/Consultancy: Roche; Advisory/Consultancy: Ipsen; Honoraria (self): Medivation; Honoraria (institution): Astellas Pharma; Research grant/Funding (institution): Nektar Therapeutics; Research grant/Funding (institution): QED. All other authors have declared no conflicts of interest.
Invited Discussant 700O and 701O
- Walter Berger (Vienna, Austria)
Q&A and live discussion
- Manuela Schmidinger (Vienna, Austria)
702O - Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study
- Sumanta Pal (Duarte, United States of America)
Abstract
Background
C, a standard-of-care for treatment of advanced RCC, promotes an immune-permissive environment which may enhance response to immune checkpoint inhibitors. COSMIC-021, a multicenter phase 1b study, is evaluating the combination of C + A in various solid tumors (NCT03170960). We present initial results in first-line ccRCC.
Methods
Patients (pts) with ccRCC were enrolled in the dose escalation (N=10) and expansion stage (N=60). Pts were enrolled sequentially to receive A 1200 mg IV Q3W with either C 40 mg (dose level 40 [DL40], N=34) or C 60 mg (DL60, N=36) PO QD in each stage. Eligible pts had ECOG PS 0-1. None had received prior systemic anticancer therapy for advanced RCC. The primary endpoint is ORR per RECIST v1.1 by investigator. Other endpoints include safety, PFS, and OS.
Results
As of Mar 27, 2020, 70 pts with ccRCC (34 at DL40 and 36 at DL60) had a median follow-up of 22.0 mo (range 17, 29) for DL40 and 11.5 (6, 28) for DL60. Baseline characteristics were similar in the two dose groups. Median age for all pts was 65 y, 76% were male, 74% had ECOG PS 0, 87% had prior nephrectomy, 77% had lung metastases, and 46% had ≥3 sites of disease. 30% were favorable, 67% were intermediate, and 3% were poor risk by IMDC criteria. Grade 3/4 TRAEs occurred in 71% of DL40 and 64% of DL60 pts, with no grade 5 TRAEs at either dose. The most common grade 3/4 TRAEs in all pts were hypertension (21% in DL40 and 14% in DL60), diarrhea (9% and 19%), hypophosphatemia (15% and 3%), and ALT increased (3% and 14%). For DL40, ORR was 47% (1 CR and 15 PRs), DCR (CR+PR+SD) was 94%, median PFS was 19.5 mo, and 12 mo PFS rate was 67%. For DL60, ORR was 58% (2 CRs and 19 PRs), DCR was 92%, median PFS was 20.4 mo, and 12 mo PFS rate was 71%. Available tumor tissue (n=40) was evaluated for PD-L1 expression, and no association with antitumor activity was shown. Increased median levels of activated peripheral cytotoxic T (+8%) and NK (+24%) cells were observed at day 21 with a concomitant decrease in immunosuppressive cells.
Conclusions
C + A demonstrated encouraging clinical activity in previously untreated pts with advanced ccRCC with an acceptable safety profile at both C doses evaluated. A phase 3 study of C + A in RCC previously treated with ICI therapy is planned.
Clinical trial identification
NCT03170960.
Editorial acknowledgement
Julie Lougheed, Exelixis.
Legal entity responsible for the study
Exelixis.
Funding
Exelixis.
Disclosure
S. Pal: Advisory/Consultancy: Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer; Research grant/Funding (self): Medivation. C-K. Tsao: Shareholder/Stockholder/Stock options: Gilead; Advisory/Consultancy: Pfizer, Clovis, Eisai, Boehringer-Ingelheim. C. Suarez: Advisory/Consultancy: Astellas, Atrazeneca, Bayer, BMS, Eusa, Ipsen, Novartis, Pfizer, Sanofi-Aventis, Roche, Merck Sharp & Dohme Corp; Speaker Bureau/Expert testimony: Bristol-Myers Squibb (Inst), Astellas, Ipsen, Pfizer; Travel/Accommodation/Expenses: Bristol-Myers Squibb (Inst), Pfizer, Roche. L. Pagliaro: Research grant/Funding (institution): Pfizer, Exelixis, Inc., Merck, Roche; Travel/Accommodation/Expenses: Merck. U.N. Vaishampayan: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Exelixis, Inc.. Y. Loriot: Honoraria (self): Roche, Astellas, Janssen, Seattle Genetics, AstraZeneca, BMS, MSD, Pfizer, Sanofi, Ipsen; Research grant/Funding (institution), Clinical trial: Roche, BMS, AstraZeneca, MSD, Pfizer, Seattle Genetics, Astellas, Janssen, Clovis, Incyte, Sanofi; Research grant/Funding (institution), Research grant: MSD, Sanofi, Janssen. S. Srinivas: Honoraria (self): Exelesis, Inc., Genentech. B.A. McGregor: Honoraria (self), Advisory/Consultancy: Bayer, Astellas, AstraZeneca, Seattle Genetics, Exelixis, Nektar, Pfizer, Janssen, Genentech and EMD Serono; Research grant/Funding (institution): BMS, Exelixis, Genentech, Seattle Genetics, Calithera. A. Panneerselvam: Shareholder/Stockholder/Stock options, Full/Part-time employment: Exelixis, Inc.. D. Curran: Shareholder/Stockholder/Stock options, Full/Part-time employment: Exelixis, Inc.. T.K. Choueiri: Full/Part-time employment: Dana Farber Cancer Hospital; Leadership role: ASCO; Dana Farber Cancer Hospital; Kidney Cancer Association; KidneyCan; NCCN; Honoraria (self): Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborsi; Advisory/Consultancy: Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; H; Research grant/Funding (institution): Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuti; Licensing/Royalties: International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immu; Travel/Accommodation/Expenses: Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; ; Non-remunerated activity/ies, Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel: Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel. N. Agarwal: Advisory/Consultancy: Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Foundation One Inc; Janssen Oncology; Lilly; Lilly; lily; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Research grant/Funding (institution): Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoS. All other authors have declared no conflicts of interest.
LBA25 - Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial
- Yann Vano (Paris, France)
Abstract
Background
Nivolumab-ipilimumab (NI) and sunitinib/pazopanib (TKI) are indicated in m-ccRCC pts with IMDC intermediate/poor and good risk groups, respectively. Based on unsupervised analysis of genes expressed in m-ccRCC, we identified 4 groups (ccrcc1-4) with immune and angiogenic high/low features which could allow to better identify responders to either N, NI or TKI. We here report final analysis results of the BIONIKK trial.
Methods
BIONIKK is an open-label, French multicenter randomized phase 2 trial evaluating N vs. NI vs. TKI in upfront m-ccRCC according to ccrcc1-4 (35-gene signature, CITsig). ccrcc1,4 and ccrcc2,3 pts were randomized to receive N vs. NI and NI vs. TKI respectively. Primary endpoint (PE): objective response rate (ORR, RECIST1.1) per treatment and group. Secondary endpoints: progression-free survival (PFS), overall survival (OS) and tolerability. 150 pts were expected in target cohort (TC). An additional cohort was included to assess inter-platform variability.
Results
From 06/2017 to 07/2019: screened=308, randomized=202 (ALL), evaluable for PE=187 with TC=154. No correlation between ccrcc1-4 and IMDC risk groups (p=0.14). ORR (TC): N=30%, NI=44%, TKI=50%, with differences according to ccrcc1-4 (table1). ORR for NI were comparable across all groups. In ccrcc1 ORR for N was half that of NI while both were comparable in ccrcc4. In ccrcc2, ORR for TKI was as high as for NI. After a median (m) FU of 16 months (mo), mPFS (TC, mo): N=4.9, NI=10.4, TKI=NR, with again observed differences according to ccrcc1-4. OS data are not mature (events:16%). No new safety signal emerged compared to published data. CITsig in frozen and FFPE samples will be presented at the meeting.
ccrcc groups 1 4 2 3 N NI N NI NI TKI NI TKI ORR, % (TC) CR 0 6 7 12 14 0 0 0 PR 21 33 43 41 34 54 25 0 SD 34 37 7 18 34 31 50 100 PD 45 24 43 29 18 15 25 0
Conclusions
We demonstrate for the 1st time in m-ccRCC pts that gene expression signatures may enable to enrich response rates. An extensive translational program is planned to identify new biomarkers.
Clinical trial identification
EudraCT: 2016-003099-28; NCT029609. Release date: November 10, 2016.
Legal entity responsible for the study
Association pour la Recherche des Thérapeutiques Innovantes en Cancérologie.
Funding
Association pour la Recherche des Thérapeutiques Innovantes en Cancérologie - Bristol Myers Squibb.
Disclosure
Y. Vano: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Merck; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Ipsen; Honoraria (institution), Advisory/Consultancy: Sanofi; Honoraria (institution), Advisory/Consultancy: Astellas; Travel/Accommodation/Expenses: Janssen. M. Bennamoun: Honoraria (institution), Advisory/Consultancy: Bristol Myers Squibb; Honoraria (institution), Advisory/Consultancy: Janssen; Honoraria (institution), Advisory/Consultancy: Sanofi; Honoraria (institution): Astellas. C.M. Chevreau: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol Myers Squibb; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Advisory/Consultancy: Novartis. D. Borchiellini: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol Myers Squibb; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy: Ipsen; Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: MSD. D. Pannier: Travel/Accommodation/Expenses: Bristol Myers Squibb; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy: Bayer; Honoraria (self), Advisory/Consultancy: Janssen. D. Maillet: Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol Myers Squibb; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen. M. Gross-Goupil: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol Myers Squibb; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen. C. Tournigand: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol Myers Squibb; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Honoraria (self), Research grant/Funding (self): Roche; Honoraria (self), Research grant/Funding (self): MSD; Honoraria (self), Travel/Accommodation/Expenses: Bayer; Honoraria (self), Research grant/Funding (self): Amgen. B. Laguerre: Honoraria (self): Bristol Myers Squibb; Honoraria (self): Ipsen; Honoraria (self): MSD; Honoraria (self): Roche; Travel/Accommodation/Expenses: Pfizer. P. Barthélémy: Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: MSD; Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: Novartis; Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Advisory/Consultancy, Travel/Accommodation/Expenses: Astellas; Advisory/Consultancy: Eusa Pharma. F. Joly: Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol Myers Squibb; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Astellas; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Honoraria (institution), Advisory/Consultancy: Bayer; Advisory/Consultancy, Travel/Accommodation/Expenses: GSK; Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi; Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Advisory/Consultancy: Clovis. G. Gravis: Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Bristol Myers Squibb; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (institution), Travel/Accommodation/Expenses: MSD; Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (institution): Astellas; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Honoraria (institution), Advisory/Consultancy: Bayer; Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi; Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen. S. Oudard: Honoraria (self): Bristol Myers Squibb; Honoraria (self): Pfizer; Honoraria (self): Novartis; Honoraria (self): Merck; Honoraria (self): Sanofi; Honoraria (self): Astellas; Honoraria (self): Janssen. All other authors have declared no conflicts of interest.
Invited Discussant 702O and LBA25
- Laurence Albiges (Villejuif, France)
Q&A and live discussion
- Manuela Schmidinger (Vienna, Austria)